RT Journal Article
T1 Validity and reliability of the Spanish fear-avoidance components scale in breast cancer survivors
A1 Gutiérrez-Sánchez, Daniel
A1 Roldán-Jiménez, Cristina
A1 Pajares, Bella
A1 Alba-Conejo, Emilio
A1 Cuesta-Vargas, Antonio
K1 Mamas - Cáncer
AB Objective:The aim of this study was to carry out a psychometric analysis of theFear-Avoidance Components Scale (FACS-Sp) in Spanish breast cancer survivors(BCS).Methods:A validation study was carried out in 154 BCS. Participants were recruitedfrom the service of Medical Oncology of the University Clinical Hospital Virgen de laVictoria, in Málaga (Spain). A psychometric analysis of internal consistency, internalstructure and convergent validity of the FACS-Sp was performed. Cronbach's alphawas calculated for internal consistency. Exploratory Factor Analysis was used todetermine the internal structure of the FACS-Sp. Convergent validity with the TampaScale of Kinesiophobia (TSK) and the Pain Catastrophizing Scale (PCS) was deter-mined using the Pearson correlation coefficient.Results:The internal consistency was high (McDonald'sω=0.91). The ExploratoryFactor Analysis yielded one factor explaining the 40.80% of total variance.Convergent validity with the TSK and the PCS was demonstrated.Conclusions:The FACS-Sp has demonstrated to be a valid and reliable measure forassessing pain-related fear avoidance in BCS based on internal consistency, structuralvalidity and convergent validity. Further studies that analyse other measurementproperties in different Spanish cancer populations are needed.
PB Wiley
YR 2021
FD 2021-08-23
LK https://hdl.handle.net/10630/24069
UL https://hdl.handle.net/10630/24069
LA eng
NO Gutiérrez-Sánchez, D., Roldán-Jiménez, C., Pajares, B., Alba, E., & Cuesta-Vargas, A. I. (2021).Validity and reliability of the Spanish fear-avoidancecomponents scale in breast cancer survivors.European Journalof Cancer Care,30(6), e13506.https://doi.org/10.1111/ecc.13506
NO Funding for open access charge: Universidad de Málaga / CBUA. This research project was partially funded by Contract No. PS16060in IBIMA between Novartis-IBIMA (Traslational Research in CancerB-01 and Clinimetric F-14).
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026